The Extracellular Signal-Regulated Protein Kinase (ERK) superfamily is the focus of intensive study due to its widespread involvement in signaling pathways in both normal and disease states. Promega's Anti-ACTIVE™ MAPK, Anti-ACTIVE™ JNK and the soon to be released Anti-ACTIVE™ p38 pAbs provide researchers with a unique and rigorously tested panel of reagents to sort out the coordinated regulation of the ERK superfamily members. These antibodies can be used for a variety of non-radioactive applications, including Western blotting and immunocytochemistry, allowing a more accurate assessment of enzyme activation in response to a variety of extracellular stimuli.
Promega Notes 63, 2.
Bruce W. Jarvis1, and Erik M. Schaefer1 and David T. Miller2